OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Saba on the Future of Treatment in Head and Neck Cancer

June 24th 2020

Nabil F. Saba, MD, FACP, discusses the future of treatment in head and neck cancer.

Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma

June 24th 2020

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL

June 24th 2020

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Sokolova on Challenges of Germline Testing in Metastatic Prostate Cancer

June 24th 2020

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer.

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Dr. Tseng on Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 23rd 2020

William W. Tseng, MD, discusses the potential role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma.

Dr. Saad on the Safety Profile of Apalutamide in M0CRPC

June 23rd 2020

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Dr. Lee on B-Cell Receptor Targeting in Relapsed/Refractory MCL

June 23rd 2020

Hun Ju Lee, MD, discusses B-cell receptor targeting in relapsed/refractory mantle cell lymphoma.

Dr. Galsky on Sequencing Questions in Urothelial Cancer

June 23rd 2020

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Dr. Weber on Research Efforts Examining Neoadjuvant Approaches in Melanoma

June 23rd 2020

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Dr. Halmos on Recent Advancements in Non–Small Cell Lung Cancer

June 23rd 2020

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

June 23rd 2020

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

June 23rd 2020

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Dr. Goldberg on Financial Toxicities Faced in Hematology

June 23rd 2020

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer

June 22nd 2020

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Dr. Sokolova on Implementing a Germline Testing Protocol for Metastatic Prostate Cancer

June 22nd 2020

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

Dr. Hill on the FDA Approval of Selinexor in DLBCL

June 22nd 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

June 22nd 2020

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Dr. Ramakrishnan on the Promise of Biosimilars in Hematology

June 22nd 2020

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

Dr. Shore on the Rationale for the Phase 3 HERO Trial in Advanced Prostate Cancer

June 22nd 2020

Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.